Orexo to complete acquisition

Orexo AB’s subsidiary Kibion AB (“Kibion”) in compiling the acceptances in the Offer to shareholders in Noster System AB (“Noster System”) has received more than 90 percent of the number of shares and votes in Noster. Accordingly, all conditions for completion of the Offer are fulfilled. “We are pleased to now be able to conclude the strategically important acquisition of Noster System,” says Lena Söderström, Managing Director of Kibion. “We have previously noted the major and continued expansive market for diagnosis of the ulcer bacteria Helicobacter pylori. The acquisition of Noster System and its product Heliprobe™ System means that Kibion, with a strengthened product portfolio and significantly increased geographic presence, takes a major step forward.” The takeover of Noster System occurs on June 9, 2006. The purchase sum for the acquisition amounts to MSEK 10.5. In addition, a supplemental payment amounting to a maximum of MSEK 7.5 may be paid conditional upon Kibion’s growth reaching certain sales targets in the next few years. Sales of Noster System’s product amounted in 2005 to MSEK 11.4, while sales of Kibion’s product Diabact® UBT in 2005 totaled MSEK 5.1. The sales of both products rose sharply compared with the preceding year. The acquisition is expected to generate a positive impact on the results for the current fiscal year. For further information, please contact: Zsolt Lavotha, President & CEO, Orexo AB Tfn: +46-18-780 88 12, e-mail: zsolt.lavotha@orexo.se Claes Wenthzel, Executive Vice President & CFO, Orexo AB Tfn: +46-18-780 88 44, e-mail: claes.wenthzel@orexo.se Lena Söderström, Managing Director Kibion AB Tfn: +46-18-780 88 40, e-mail: lena.soderstrom@kibion.se